<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443426</url>
  </required_header>
  <id_info>
    <org_study_id>KETO- CHF 1-10-72-362-18</org_study_id>
    <nct_id>NCT04443426</nct_id>
  </id_info>
  <brief_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular and Metabolic Effects</brief_title>
  <acronym>KETO-CHF</acronym>
  <official_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular and Metabolic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ketone body 3-hydroxybutyrate (3-OHB) is a naturally occurring energy substrate, and is
      associated with increased life span and improved health. We have previously shown that
      intravenous 3-OHB treatment increases myocardial blood flow &gt; 70% in healthy humans and data
      from our group show that 3-OHB increases cardiac output by 40 % in patients with heart
      failure.

      In this study the investigators aim to investigate:

        1. If this effect is reproducible with a comercially available oral ketone supplement

        2. If the effect persists after one month treatment.

        3. The changes in whole-body substrate metabolism durin ketone supplementation in patients
           with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure (HF) is a major public health issue because the disease affects 1-2% of the
      Western population and the lifetime risk of HF is 20%. HF is responsible for 1-2% of all
      healthcare expenditures. Despite major improvements in the management and care of patients
      with HF, the 1-year mortality in patients with HF is 13 % and &gt;50% of HF-patients is admitted
      during a 2.5 year period. Furthermore patients with HF have markedly decreased physical
      capacity and quality of life. Thus, there is a need for new treatment modalities in this
      group of patients.

      Ketone bodies are produced in the liver and are of vital importance in the human body for
      energy generation in the heart and brain during fasting, exercise and severe illness. Ketosis
      can be safely obtained using dietary supplements and can increase exercise capacity in
      athletes. The most important ketone bodies are 3-hydroxybutyrate (3-OHB) and acetoacetate.
      Recently, it was demonstrated that patients with severe HF have increased myocardial
      utilization of the ketone body 3-hydroxybutyrate.

      We have shown, using positron emission tomography, that ketone body infusion reduces
      myocardial glucose uptake and increases myocardial blood flow in healthy subjects. Data from
      another study conducted by our group show a 40% increase in cardiac output during infusion of
      3-OHB.

      Presently there are no data on the clinical cardiovascular and metabolic effects of long-term
      oral ketone-supplementation in patients with chronic HF.

      In this study the investigators will whether ketosis obtained by oral ketone supplements
      affects hemodynamics, contractile function and whole-body substrate metabolism in patients
      with heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output (L/min)</measure>
    <time_frame>1 day</time_frame>
    <description>Right Heart Catherization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-Body Substrate Metabolism</measure>
    <time_frame>1 day</time_frame>
    <description>Assessed by tracer kinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle Ejection Fraction (%)</measure>
    <time_frame>1 day</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular filling pressure (mmHg)</measure>
    <time_frame>1 day</time_frame>
    <description>Right Heart Catherization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise-induced changes in Cardiac Output (L/min)</measure>
    <time_frame>1 day</time_frame>
    <description>Right Heart Catherization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity (Watts)</measure>
    <time_frame>1 day</time_frame>
    <description>Standardized CPX-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vO2 Max (mL/min)</measure>
    <time_frame>1 day</time_frame>
    <description>Standardized CPX-Test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ketosis</condition>
  <condition>Ketonemia</condition>
  <arm_group>
    <arm_group_label>3-Hydroxybutyrate followed by Placebo treatment (one month)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study in 20 HFrEF-patients. Investigated by right heart catherization, echocardiography, cardiopulmonary exercise test and whole-body substrate metabolism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by 3-Hydroxybutyrate treatment (one month)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study in 20 HFrEF-patients. Investigated by right heart catherization, echocardiography, cardiopulmonary exercise test and whole-body substrate metabolism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose placebo or oral 3-hydroxybutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over pilot study in 8 patients receiving single-dose oral 3-hydroxybutyrate and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral 3-hydroxybutyrate salts</intervention_name>
    <description>Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.</description>
    <arm_group_label>3-Hydroxybutyrate followed by Placebo treatment (one month)</arm_group_label>
    <arm_group_label>Placebo followed by 3-Hydroxybutyrate treatment (one month)</arm_group_label>
    <arm_group_label>Single dose placebo or oral 3-hydroxybutyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate Placebo</intervention_name>
    <description>Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.</description>
    <arm_group_label>3-Hydroxybutyrate followed by Placebo treatment (one month)</arm_group_label>
    <arm_group_label>Placebo followed by 3-Hydroxybutyrate treatment (one month)</arm_group_label>
    <arm_group_label>Single dose placebo or oral 3-hydroxybutyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Heart Failure;

          -  NYHA class II-III

          -  Left Ventricular Ejection Fraction &lt;40%

        Exclusion Criteria:

          -  Diabetes or HbA1c &gt; 48 mmol/mol

          -  Significant cardiac valve disease,

          -  Severe stable angina pectoris

          -  Severe comorbidity as judged by investigator,

          -  Inability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian H Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus Universitetshospital - Department of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik S Wiggers, DMSc</last_name>
    <phone>+4578452026</phone>
    <email>henrikwiggers@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristian H Christensen, MD</last_name>
    <phone>+4526603577</phone>
    <email>krstchri@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian H Christensen, MD</last_name>
      <phone>+4526603577</phone>
      <email>krstchri@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04443426/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

